FibroGen Inc (NAS:FGEN)
$ 1.3 0.02 (1.56%) Market Cap: 129.32 Mil Enterprise Value: 101.67 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 57/100

FibroGen Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript

Jun 09, 2020 / 07:00PM GMT
Release Date Price: $35.79 (+6.49%)
Kyuwon Choi
Goldman Sachs Group Inc., Research Division - Equity Analyst

Okay. Good afternoon, one. I'm Paul Choi, the SMid cap biotechnology analyst at Goldman Sachs. We'll continue with our next session here, which is FibroGen. And I'm very pleased to introduce from management, Enrique Conterno, who's, I think, a well-known quantity to investors. He's the CEO here at FibroGen.

I think as with other sessions, what we'll do is let Enrique do a few brief introductory remarks and give us an overview of what he's finding to be going on at FibroGen. And then we'll proceed with the Q&A. (Operator Instructions) And with that, Enrique, I'll turn it over to you for some opening comments.

Enrique A. Conterno
FibroGen, Inc. - CEO & Director

Very good, Paul. Thank you very much for the invitation. It's a pleasure to be here.

I'm very excited with the agenda that we have at FibroGen. As I've mentioned in the past, we are very committed to 3 overarching goals. #1 is to ensure that regulatory and commercial success of roxadustat, and we are

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot